Introduction {#section1-1533033819894308}
============

Acute myeloid leukemia (AML) is a group of heterogeneous hematological diseases, characterized by abnormal accumulation of blast cells in the bone marrows and peripheral blood.^[@bibr1-1533033819894308]^ Acute myeloid leukemia is the most common myeloid leukemia; the incidence rate is largely age-related, with a prevalence of 3.8 cases per 100 000 rising to 17.9 cases per 100 000 adults aged 65 years and older. Risk factors of the disease include exposure to ionizing radiation, benzene, and cytotoxic chemotherapy.^[@bibr1-1533033819894308]^ Cytogenetic abnormalities have been widely used as cytogenetic markers for evaluating the prognosis of patients with AML, such as positive prognostic factors T(8;21) and inv(16)/t(16;16) and negative prognostic factor inv(3)/t(3;3).^[@bibr2-1533033819894308]^ Although cytogenetic alterations show clinical utility for risk stratification, they might not be applicable for a large fraction of AML samples without structural abnormalities.^[@bibr3-1533033819894308],[@bibr4-1533033819894308]^ Therefore, identifying new prognostic biomarkers is critical to the survival of patients with AML.

The solute carrier family 2 (SLC2) genes encode glucose transporter (GLUT) proteins, which are members of the major facilitator superfamily of membrane transporters. The GLUT proteins comprise 14 family members that could be stratified into 3 classes based on sequence similarity: class 1 (GLUTs 1-4, 14), class 2 (GLUTs 5, 7, 9, and 11), and class 3 (GLUTs 6, 8, 10, 12, and 13).^[@bibr5-1533033819894308]^ Of the 14 GLUT proteins, the roles of GLUT1 have been well established in a wide range of cancer types. Expression of GLUT1 is associated with aggressive tumor grade and poor survival outcomes in breast cancer^[@bibr6-1533033819894308]^ and thyroid cancer.^[@bibr7-1533033819894308]^ The GLUT1 expression was significantly related to tumor differentiation, lymph node metastasis, tumor size, advanced tumor stages, and overall survival (OS) of patients with lung cancer. The increased expression of GLUT1 was associated with shorter disease-free survival in lung cancer.^[@bibr8-1533033819894308]^ Expression of GLUT1 protein was significantly correlated with advanced tumor stages and poor differentiation in patients with hepatocellular carcinoma. Inhibition of GLUT1 expression impaired the proliferative and migratory capabilities of hepatocellular carcinoma cells.^[@bibr9-1533033819894308]^

Up to date, it remains unknown with respect to the associations among OS, clinical characteristics, and expression of SLC2 family genes in AML. Therefore, this study was conducted to address these issues by a variety of statistical methods using a large set of AML patient data from The Cancer Genome Atlas (TCGA)^[@bibr10-1533033819894308]^ and Gene Expression Omnibus (GEO) database.

Materials and Methods {#section2-1533033819894308}
=====================

Acquisition of SLC2 Family Gene Expression and Clinical Feature Data {#section3-1533033819894308}
--------------------------------------------------------------------

Since French--American--British classification M3 has distinct biologic features and favorable outcome compared to other subtypes, only non-M3 patients were included in the study. Expression of SLC2 family gene, *IDH1, IDH2, DNMT3A, NPM1, FLT3,* and *CEBPA* mutation and clinical feature data of 157 patients with non-M3 AML were obtained from the TCGA database^[@bibr10-1533033819894308]^ (TCGA data set). Clinicopathologic characteristics analyzed in the study included patients' age, gender, percentage of bone marrow blast cells (PBMBC), cytogenetic risk, CD33, CD34, *IDH1, IDH2, DNMT3A, NPM1*, *FLT3*, *CEBPA* mutation statuses, neoadjuvant treatment, survival status, and follow-up data. The *SLC2A2* gene which has no expression values in 90% AML samples was eliminated from the study. To validate the associations of SLC2 family gene expression with OS, SLC2 family gene expression and clinical data of 397 non-M3 AML patients were downloaded from the Tyner study^[@bibr11-1533033819894308]^ (Validation dataset) in the GEO database. Clinicopathologic characteristics in the validation data set included patients' age, gender, PBMBC, cytogenetic risk, *IDH1, DNMT3A, NPM1*, *FLT3-IDT*, and *CEBPA* mutation statuses, chemotherapy, bone marrow transplant, targeted therapy, survival status, and follow-up data. All patients provided written inform consent. As the data sets included in the study were downloaded from public databases, the study did not need the approval of an ethics committee.

Associations Among Clinical Characteristics, Mortality, and Expression of SLC2 Family Genes {#section4-1533033819894308}
-------------------------------------------------------------------------------------------

Associations between clinical characteristics, mortality, and expression of SLC2 family genes were analyzed by various statistical methods. Student *t* test was used to compare the age and PBMBC between patients with AML who died and were alive. Fisher exact test was used to analyze the associations between mortality and patients' gender, cytogenetic risk, CD33, CD34, *IDH1, IDH2, DNMT3A, NPM1, FLT3*, *CEBPA* mutation statuses, chemotherapy, bone marrow transplant, and targeted therapy. Linear regression model was applied to evaluate the associations between clinical features and SLC2 family gene expression. Pearson correlation was used to analyze the correlation between different SLC2 messenger RNA (mRNA) expression. All statistical analyses were performed in R (version 3.2.2), and *P* \< .05 indicates statistical significance. Protein--protein interaction (PPI) network was built by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) to characterize the interactions of SLC2 family genes at the protein level.^[@bibr12-1533033819894308]^

Associations Between OS and SLC2 Family Gene Expression {#section5-1533033819894308}
-------------------------------------------------------

To characterize the associations of SLC2 family gene expression and patients' OS in the TCGA and validation data sets, receiver operating characteristic (ROC) curves were built with the function of ROC of the R package of pROC.^[@bibr13-1533033819894308]^ The optimal cutoff values were determined by the pROC package, and patients with AML were divided into high and low expression groups based on the cutoff values. "High-expression" group referred to the patients who exhibited higher SLC2 family gene expression levels than the cutoff values, whereas the "low-expression" group was those patients who showed lower expression levels than the cutoff values. Kaplan-Meier survival analysis was performed, and the log-rank test was utilized to compare the difference in survival rates between the high- and low-expression groups using the R package of survival.^[@bibr14-1533033819894308]^ To evaluate the odds ratios (OR) of high SLC2 family gene expression on patients' OS, univariate and multivariate survival analyses were performed using logistic regression model. Both OR and 95% confidence interval (CI) of OR were extracted from the univariate and multivariate survival analyses; *P* \< .05 indicates statistical significance.

Results {#section6-1533033819894308}
=======

General Characteristics of 157 Patients With AML in the TCGA Data Set {#section7-1533033819894308}
---------------------------------------------------------------------

The mean age of 157 patients with AML was 56.04, and the minimum and maximum age were 18 and 88 years, respectively. The average PBMBC was 41.5 at diagnosis. Cytogenetic risk evaluation showed 17, 102, and 36 patients had favorable, intermediate, and poor outcomes, respectively, and the cytogenetic risk for 2 patients was missing. In all, 118 and 107 cancer samples showed CD33- and CD34-positive results, while 13 and 24 AML samples were CD33- and CD34 negative, respectively. In all, 16, 17, 43, 48, 44, and 13 AML samples had *IDH1, IDH2, DNMT3A, NPM1, FLT3*, and *CEBPA* mutations, respectively. Forty-three patients with AML underwent neoadjuvant treatment, and 114 patients didn't have neoadjuvant treatment. On the last day of follow-up, 109 patients with AML died, and 48 were alive. The mean follow-up time was 517.33 days (interquartile range, 153-699 days).

The Associations Between Mortality and Clinicopathologic Characteristics in AML {#section8-1533033819894308}
-------------------------------------------------------------------------------

Among the clinicopathologic characteristics, patients with older age exhibited significantly worse mortality than those with younger age (*P* \< .0001, Student *t* test, [Figure 1A](#fig1-1533033819894308){ref-type="fig"} and [Table 1](#table1-1533033819894308){ref-type="table"}). Patients' mortality was significantly associated with cytogenetic risk (*P* = .001, Fisher exact test; [Table 1](#table1-1533033819894308){ref-type="table"}). However, the remaining factors, gender, CD33, CD34 status, PBMBC, *IDH1, IDH2, DNMT3A, NPM1, FLT3, CEBPA* mutations, and neoadjuvant treatment did not exhibit a significant association with OS in patients with AML (*P* \> .05 for all cases, Fisher exact test or Student *t* test; [Figure 1B](#fig1-1533033819894308){ref-type="fig"} and [Table 1](#table1-1533033819894308){ref-type="table"}).

![Patients' age (A) and percentage of bone marrow blast cells (B) were significantly different between patients with AML who were died or alive. AML indicates acute myeloid leukemia.](10.1177_1533033819894308-fig1){#fig1-1533033819894308}

###### 

Association Between the Clinicopathologic Characteristics and Patients' Mortality in Patients With AML.

![](10.1177_1533033819894308-table1)

  Variables               Group       Alive   Dead    *P* Value   Statistical Method
  ----------------------- ----------- ------- ------- ----------- --------------------
  Age                                 49.63   58.86   .00         Student *t* test
  PBMBC                               44.25   40.28   .48         Student *t* test
  Gender                  Female      21      50      .86         Fisher exact test
  Male                    27          59                          
  CD33                    Negative    5       8       .53         Fisher exact test
  Positive                34          84                          
  CD34                    Negative    9       15      .63         Fisher exact test
  Positive                34          73                          
  Cytogenetic risk        Favorable   10      7       .03         Fisher exact test
  Intermediate            30          72                          
  Poor                    8           28                          
  *IDH1* mutation         Mutant      7       9       .26         Fisher exact test
                          Wild-type   41      100                 
  *IDH2* mutation         Mutant      5       12      1           Fisher exact test
                          Wild-type   43      97                  
  *DNMT3A* mutation       Mutant      10      33      .25         Fisher exact test
                          Wild-type   38      76                  
  *NPM1* mutation         Mutant      15      33      1           Fisher exact test
                          Wild-type   33      76                  
  *CEBPA* mutation        Mutant      4       9       1           Fisher exact test
                          Wild-type   44      100                 
  *FLT3* mutation         Mutant      12      32      .7          Fisher exact test
                          Wild-type   36      77                  
  Neoadjuvant treatment   Yes         12      31      .7          Fisher exact test
                          No          36      78                  

Abbreviations: AML, acute myeloid leukemia; PBMBC, percentage of bone marrow blast cells.

The Associations Between Clinicopathologic Characteristics and SLC2 Family Gene Expression in AML {#section9-1533033819894308}
-------------------------------------------------------------------------------------------------

A linear regression model was applied to study the associations between clinicopathologic characteristics and mRNA expression values of SLC2 family genes. Patients' age was positively correlated with *SLC2A5, SLC2A8*, and *SLC2A10* mRNA expression. The PBMBC was negatively correlated with *SLC2A1*, *SLC2A3, SLC2A4, SLC2A6, SLC2A9, SLC2A10*, and *SLC2A14* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). CD33 status was negatively associated with *SLC2A4, SLC2A7*, and *SLC2A14*. CD34 status was positively associated with *SLC2A1* and negatively associated with *SLC2A9* and *SLC2A13* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). Cytogenetic risk was positively associated with *SLC2A1, SLC2A4* and *SLC2A5* and negatively associated with *SLC2A7* and *SLC2A13* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). *IDH1* mutation was positively associated with *SLC2A13* expression. *NPM1* mutation was positively associated with *SLC2A13* and negatively associated with *SLC2A4, SLC2A7, SLC2A12*, and *SLC2A14* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). *CEBPA* mutation was positively associated with *SLC2A1* and negatively associated with *SLC2A8* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). *FLT3* mutation was negatively correlated with *SLC2A1*, *SLC2A4, and SLC2A7* expression ([Table 2](#table2-1533033819894308){ref-type="table"}). Neoadjuvant treatment was negatively correlated with *SLC2A1* and *SLC2A4* expression ([Table 2](#table2-1533033819894308){ref-type="table"}).

###### 

Linear Regression Analysis Between Clinicopathologic Characteristics and SLC2 Family Gene Expression in Patients With AML.^a^

![](10.1177_1533033819894308-table2)

  Gene      Age   Gender (male)   PBMBC   CD33   CD34   Cytogenetic Risk   *IDH1* Mutation   *IDH2* Mutation   *DNMT3A* Mutation   *NPM1* Mutation   *CEBPA* Mutation   *FLT3* Mutation   Neoadjuvant Treatment
  --------- ----- --------------- ------- ------ ------ ------------------ ----------------- ----------------- ------------------- ----------------- ------------------ ----------------- -----------------------
  SLC2A1                          \-             \+     \+                                                                                           \+                 \-                \-
  SLC2A3                          \-                                                                                                                                                      
  SLC2A4                          \-      \-            \+                                                                         ---                                  \--               \-
  SLC2A5    \+                                          ++                                                                                                                                
  SLC2A6                          \-                                                                                                                                                      
  SLC2A7                                  \-            \-                                                                         \-                                   \-                
  SLC2A8    \+                                                                                                                                       \-                                   
  SLC2A9                          ---            \-                                                                                                                                       
  SLC2A10   ++                    \--                                                                                                                                                     
  SLC2A11                                                                                                                                                                                 
  SLC2A12                                                                                                                          \-                                                     
  SLC2A13         \-                             ---    \-                 \+                                                      +++                                                    
  SLC2A14                         ---     \-                                                                                       \-                                                     

Abbreviations: AML, acute myeloid leukemia; SLC2, solute carrier family 2; PBMBC, percentage of bone marrow blast cells.

^a^ +, ++, +++ denote positive correlation with *P* value \< .05, *P* value \< .01, and *P* value \< .001, respectively. -, \--, \-\-- stand for negative correlation with *P* value \< .05; *P* value \< .01, and *P* value \< .001, respectively.

The Gene--Gene and Protein--Protein Interactions of SLC2 Family Genes {#section10-1533033819894308}
---------------------------------------------------------------------

In order to characterize the coexpression between different SLC2 family gene expression in AML, the correlations of SLC2 family gene expression were analyzed. The expression of SLC2 family genes was highly correlated; of the 13 SLC2 family members, *SLC2A7* was significantly coexpressed with *SLC2A4, SLC2A5, SLC2A6, SLC2A9,* and *SLC2A11*. *SLC2A4, SLC2A6, SLC2A9, SLC2A11,* and *SLC2A14* showed significant correlation with the expression of 4 other family members (*P* \< .05 for all cases, Pearson correlation; [Figure 2A](#fig2-1533033819894308){ref-type="fig"}). Whereas, no significant correlation was observed between *SLC2A12* and other SLC2 family members (*P* \> .05 for all cases, Pearson correlation; [Figure 2A](#fig2-1533033819894308){ref-type="fig"}). We also applied STRING to develop the PPI network for SLC2 family genes. The PPI network comprised 12 nodes and 19 edges, with a median node degree of 3.17 ([Figure 2B](#fig2-1533033819894308){ref-type="fig"}). As expected, the PPI network exhibited more interactions than the randomly imputed interactions using similar size of proteins (PPI enrichment *P* value \<.0001). The gene--gene and PPI networks indicated that the SLC2 family genes were coexpressed and exhibited extensive homology at the protein level.

![The solute carrier family 2 gene--gene and protein--protein interaction networks. A, Gene--gene interaction network of SLC2 family genes. B, Protein--protein interaction network of SLC2 family genes. Network nodes and edges represent proteins and protein--protein associations, respectively. Light blue lines represent known interactions from the curated Kyoto Encyclopedia of Genes and Genomes database, purple lines represent experimentally determined protein--protein interactions, green lines denote genes that are frequently observed in each other's genomic neighborhood, black lines stand for genes where expression are correlated across a large number of experiments, dark blue lines indicate gene families with similar occurrence patterns across genomes, and light gray lines indicate proteins with amino acid sequence similarity. SLC2 indicates the solute carrier family 2.](10.1177_1533033819894308-fig2){#fig2-1533033819894308}

Survival Analyses Between Patient Mortality and SLC2 Family Gene Expression in AML {#section11-1533033819894308}
----------------------------------------------------------------------------------

To evaluate the predictive capability of SLC2 family gene expression for patients' survival, ROC curves were built with the R package of pROC. Then, the 157 patients with AML in the TCGA data set were divided into low- and high-expression groups based on cutoff values. Kaplan-Meier survival analysis suggested that patients with high expression levels of *SLC2A4, SLC2A12*, and *SLC2A13* exhibited a favorable prognosis. In contrast, patients with high expression levels of *SLC2A5, SLC2A8*, and *SLC2A10* were associated with a poor prognosis (*P* \< .05 for all cases, log rank test; [Figure 3](#fig3-1533033819894308){ref-type="fig"} and Supplementary Table 1). Univariate analysis using logistic regression model showed that decreased *SLC2A4* and *SLC2A13* expression was significantly associated with increased mortality (*P* = .04, OR:0.47, 95% CI: 0.23-0.95; *P* = .01, OR: 0.34, 95% CI: 0.14-0.75, respectively). Increased *SLC2A5* and *SLC2A10* expression was associated with increased mortality (*P* = .00, OR: 3.42, 95% CI: 1.63-7.69; *P* = .01, OR: 2.59, 95% CI: 1.3-5.33, respectively). Then, multivariate analyses were applied between patients' survival and the mortality-associated features, including patients' age, cytogenetic risk, and *SLC2A4, SLC2A5, SLC2A10*, and *SLC2A13* expression levels. Multivariate survival analyses confirmed that high *SLC2A5* and *SLC2A10* expression and low *SLC2A13* expression were associated with increased mortality (*P* = .00, OR: 4.05, 95% CI: 1.73-10.22; *P* = .00, OR: 3.66, 95% CI: 1.54-9.25; and *P* = .01, OR: 0.26, 95% CI: 0.09-0.68, respectively; [Table 3](#table3-1533033819894308){ref-type="table"}).

![Kaplan-Meier survival analysis shows SLC2A5 (A), SLC2A10 (B), and SLC2A13 (C) expression levels were significantly associated with clinical outcomes in the TCGA data set. TCGA indicates The Cancer Genome Altas.](10.1177_1533033819894308-fig3){#fig3-1533033819894308}

###### 

Multivariate Analyses Between Patients' Overall Survival and the Mortality-Associated Features and SLC2A4, SLC2A5, SLC2A10, and SLC2A13 Expression Levels.

![](10.1177_1533033819894308-table3)

  Clinical Features   OR (95% CI)         *P* Value
  ------------------- ------------------- -----------
  Age                 1.04 (1.01-1.06)    .01
  Cytogenetic risk    1.17 (0.56-2.51)    .67
  *SLC2A4*            0.52 (0.23-1.15)    .11
  *SLC2A5*            4.05 (1.73-10.22)   .00
  *SLC2A10*           3.66 (1.54-9.25)    .00
  *SLC2A13*           0.26 (0.09-0.68)    .01

Abbreviations: OR, odd ratio; CI, confidence interval.

Validation Analyses {#section12-1533033819894308}
-------------------

In order to further validate the findings mentioned earlier, the associations among *SLC2* family gene expression and mortality, clinical factors were analyzed in 397 non-M3 AML samples of the validation data set. The detailed clinical characteristics of patients with AML in the validation set are shown in Supplementary Table 2. As expected, patient's age, cytogenetic risk, chemotherapy, bone marrow transplant, and targeted therapy exhibited a significant association with OS in patients with AML (*P* \< .05 for all cases, Fisher exact test or Student *t* test, Supplementary Table 2). The other factors PBMBC, gender*, IDH1, DNMT3A, NPM1*, *FLT3-IDT,* and *CEBPA* mutation statuses did not show significant association with OS in patients with AML (*P* \> .05 for all cases, Fisher exact test or Student *t* test; Supplementary Table 2). The associations between SLC2 gene expression and clinical factors are presented in Supplementary Table 3. Many SLC2 genes were significantly correlated with clinical characteristics in patients with AML (*P* \< .05 for all cases, linear regression model; Supplementary Table 3). Kaplan-Meier survival analysis suggested that patients with high expression levels of *SLC2A3, SLC2A4, SLC2A13*, and *SLC2A14* exhibited a favorable prognosis. In contrast, patients with high expression of *SLC2A5* and *SLC2A10* were associated with a poor prognosis (*P* \< .05 for all cases, log rank test; [Figure 4](#fig4-1533033819894308){ref-type="fig"}). Univariate analysis using logistic regression model showed that decreased *SLC2A13* expression was significantly associated with increased mortality (*P* = .00, OR: 0.54, 95% CI: 0.35-0.81). Increased *SLC2A5* and *SLC2A10* expression was associated with increased mortality (*P* = .00, OR:2.04, 95% CI: 1.31-3.21; *P* = .02, OR:1.88, 95% CI: 1.12-3.22). Then, multivariate analyses were applied between patients' survival and the mortality-associated features, including patients' age, cytogenetic risk, chemotherapy, bone marrow transplant, targeted therapy, and *SLC2A5, SLC2A10,* and *SLC2A13* expression levels. Multivariate survival analyses confirmed that high *SLC2A10* expression was associated with increased mortality (*P* = .03, OR: 1.97, 95% CI: 1.07-3.73; Supplementary Table 4).

![Kaplan-Meier survival analysis shows SLC2A5 (A), SLC2A10 (B), and SLC2A13 (C) expression levels were significantly associated with clinical outcomes in the validation data set.](10.1177_1533033819894308-fig4){#fig4-1533033819894308}

Discussion {#section13-1533033819894308}
==========

In the present study, we investigated the associations between mortality, clinicopathologic characteristics, and SLC2 family gene expression in AML. As expected, we found patients' age and cytogenetic risk were significantly associated with mortality in patients with AML. Recent study has revealed *IDH1, IDH2*, *DNMT3A, NPM1, FLT3-IDT*, and *CEBPA* mutations and mixed lineage leukaemia translocations improve risk stratification for patients with AML.^[@bibr15-1533033819894308][@bibr16-1533033819894308]-[@bibr17-1533033819894308]^ However, *IDH1, IDH2, DNMT3A, NPM1, FLT3-IDT,* and *CEBPA* mutations were not associated with mortality in this study. This might be because the number of patients with AML is limited, and the follow-up time is relatively short; therefore, a large number of AML samples with long-term follow-up might be needed to validate the associations between *IDH1, IDH2, DNMT3A, NPM1, FLT3-IDT*, *CEBPA* mutation and OS in AML.

Many SLC2 family members are significantly correlated with clinical features of patients with AML. We found 3 genes, *SLC2A5*, *SLC2A10,* and *SLC2A13*, showed significant associations with mortality, which might have clinical values. *SLC2A10* encodes a member of the GLUT family. The encoded protein, *GLUT10*, plays an important role in the regulation of glucose homeostasis. Mutations in this gene have been associated with arterial tortuosity syndrome^[@bibr18-1533033819894308]^. To date, the role of *SLC2A10* in AML remains unclear, and this is the first study that reported the association of *SLC2A10* with OS in AML. The increased *SLC2A10* expression enhances uptake and utilization of glucose in AML cells, leading to increased viability of AML cells and inferior OS of patients with AML.

*SLC2A5* encodes the protein of GLUT5, which plays a major role in the fructose transportation in mammalian cells.^[@bibr19-1533033819894308]^ Overexpression of *SLC2A5* has been observed in lung adenocarcinoma,^[@bibr20-1533033819894308]^ Philadelphia chromosome-positive acute lymphoblastic leukemia,^[@bibr21-1533033819894308]^ and AML.^[@bibr22-1533033819894308]^ In line with the finding of this study, patients with overexpression of *SLC2A5* have poor prognosis in lung cancer^[@bibr20-1533033819894308]^ and AML.^[@bibr22-1533033819894308]^ The increased expression in the sugar transporter GLUT5 encoded by SLC2A5 enhanced uptake and utilization of fructose in the primary leukemic cells of patients with AML, which caused enhanced proliferation of AML cells and inferior OS. *E*xpression of *SLC2A5* was significantly correlated with grade of differentiation, pelvis invasion, and breaking capsule in clear cell carcinoma.^[@bibr23-1533033819894308]^ Silencing *SLC2A5* expression inhibits cell proliferation, invasion, and induces cellular apoptosis. Enhanced expression of *SLC2A5* increases cell proliferation, invasion, and tumorigenic capability in lung cancer.^[@bibr20-1533033819894308]^

*SLC2A13*, as a proton (H+) myo-inositol transporter^[@bibr24-1533033819894308]^, has an important role in the metabolism of phosphatidyl inositol and could accomplish tumorigenic effect by influencing the function of Akt.^[@bibr25-1533033819894308]^ *SLC2A13* is more frequently present in lung cancer samples with good differentiation and without lymph node invasion.^[@bibr26-1533033819894308]^ *SLC2A13* is consistently increased in the cancer stem cells in oral squamous cell carcinoma, it might function as a potential marker for cancer stem cells.^[@bibr27-1533033819894308]^ So far, there is no study regarding the involvement of *SLC2A13* in AML, and for the first time, our study reported increased expression of *SLC2A13* was associated with decreased mortality in patients with AML. As *SLC2A13* accomplishes tumorigenic effect by influencing the function of Akt, the impact of *SLC2A13* expression on the OS of patients with AML is possibly mediated by regulating the function of Akt; however, the detailed mechanism still needs further studies. *SLC2A5*, *SLC2A10*, and *SLC2A13* expression profiling may have certain advantage and clinical applicability in patients with AML when compared to prognosis assessment by either cytogenetics or mutation profiling which are limited to a fraction of patients with AML. Patients with AML with low expression of *SLC2A13* and high expression of *SLC2A5* and *SLC2A10* are expected to have an inferior prognosis. Therefore, more aggressive treatment or frequent follow-up may be needed for these patients. *SLC2A5, SLC2A10*, and *SLC2A13* may also provide promising cancer targets for patients with AML. For instance, drugs inhibiting *SLC2A5* gene significantly suppressed fructose-induced proliferation, colony growth, and migration of AML cells with enhanced fructose utilization.^[@bibr22-1533033819894308]^

Conclusion {#section14-1533033819894308}
==========

In conclusion, high *SLC2A13* expression is associated with decreased mortality, whereas, high *SLC2A5 and SLC2A10* expression is associated with increased mortality in patients with AML. The solute carrier family 2 gene expression represents a potentially prognostic biomarker to predict survival in AML.

Supplemental Material {#section15-1533033819894308}
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